Atjaunināt sīkdatņu piekrišanu

E-grāmata: Animal Models for Assessing Countermeasures to Bioterrorism Agents

  • Formāts: 152 pages
  • Izdošanas datums: 09-Dec-2011
  • Izdevniecība: National Academies Press
  • Valoda: eng
  • ISBN-13: 9780309219105
Citas grāmatas par šo tēmu:
  • Formāts - PDF+DRM
  • Cena: 3,93 €*
  • * ši ir gala cena, t.i., netiek piemērotas nekādas papildus atlaides
  • Ielikt grozā
  • Pievienot vēlmju sarakstam
  • Šī e-grāmata paredzēta tikai personīgai lietošanai. E-grāmatas nav iespējams atgriezt un nauda par iegādātajām e-grāmatām netiek atmaksāta.
  • Formāts: 152 pages
  • Izdošanas datums: 09-Dec-2011
  • Izdevniecība: National Academies Press
  • Valoda: eng
  • ISBN-13: 9780309219105
Citas grāmatas par šo tēmu:

DRM restrictions

  • Kopēšana (kopēt/ievietot):

    nav atļauts

  • Drukāšana:

    nav atļauts

  • Lietošana:

    Digitālo tiesību pārvaldība (Digital Rights Management (DRM))
    Izdevējs ir piegādājis šo grāmatu šifrētā veidā, kas nozīmē, ka jums ir jāinstalē bezmaksas programmatūra, lai to atbloķētu un lasītu. Lai lasītu šo e-grāmatu, jums ir jāizveido Adobe ID. Vairāk informācijas šeit. E-grāmatu var lasīt un lejupielādēt līdz 6 ierīcēm (vienam lietotājam ar vienu un to pašu Adobe ID).

    Nepieciešamā programmatūra
    Lai lasītu šo e-grāmatu mobilajā ierīcē (tālrunī vai planšetdatorā), jums būs jāinstalē šī bezmaksas lietotne: PocketBook Reader (iOS / Android)

    Lai lejupielādētu un lasītu šo e-grāmatu datorā vai Mac datorā, jums ir nepieciešamid Adobe Digital Editions (šī ir bezmaksas lietotne, kas īpaši izstrādāta e-grāmatām. Tā nav tas pats, kas Adobe Reader, kas, iespējams, jau ir jūsu datorā.)

    Jūs nevarat lasīt šo e-grāmatu, izmantojot Amazon Kindle.

The Transformational Medical Technologies (TMT) has been a unique component of the U.S. Department of Defense (DoD) medical biodefense efforts since 2006. Its mission is to advance countermeasure research and development in support of the broader goal of the DoD to protect warfighters from emerging infectious diseases and future genetically engineered biological weapons. The TMT, using advanced science and technology approaches, focused on the development of roadspectrum countermeasures that target common host and pathogen pathways or enhance the host's immune response. Many of these pathogens are lethal or cause such debilitating diseases in humans that it is ethically inappropriate to test the efficacy of these countermeasures in human volunteers. In lieu of human participants, these products may be tested in animals and approved for human use under the provisions of the Food and Drug Administration (FDA)'s 2002 Animal Rule. The reliance on animal models for the development and licensure of medical countermeasures against biothreats is challenging for a number of reasons.



The ad hoc Committee on Animal Models for Assessing Countermeasures to Bioterrorism Agents prepared a consensus report that would address the challenges stemming from developing and testing medical countermeasures against biothreat agents in animal models. Animal Models for Assessing Countermeasures to Bioterrorism Agents evaluates how well the existing TMT-employed or candidate animal models reflect the pathophysiology, clinical picture, and treatment of human disease as related to the agents of interest. The report addresses the process and/or feasibility of developing new animal models for critical biodefense research, placing emphasis on the need for a robust and expeditious validation process in terms of the FDA's Animal Rule. The report also evaluates alternatives to the use of animal models based on the premise of the Three Rs.

Table of Contents



Front Matter Summary 1 Introduction 2 Evaluation of Current and Future TMT-Used Animal Models 3 Ethical and Regulatory Challenges in the Development of Countermeasures 4 Developing New Animal Models for Biodefense Research 5 Alternative Approaches to Animal Testing for Biodefense Countermeasures Appendix A: The Animal Rule Appendix B: Draft Guidance for Industry Appendix C: Developing Animal Models for Use in Animal Rule Licensure: The NIAID Approach Appendix D: Presentations to the Committee Appendix E: Statement of Task Appendix F: About the Authors
Summary 1(6)
1 Introduction
7(8)
The Nature of Threat
7(1)
Addressing the Unknown Threat through the Transformational Medical Technologies Initiative
8(3)
Statement of Task
11(1)
Approach by the Committee
12(1)
References
12(3)
2 Evaluation of Current and Future TMT-Used Animal Models
15(24)
Animal Models Are Analogous, Not Homologous Systems
17(1)
Considerations for Animal Models for Countermeasure Development
18(1)
Filoviruses
19(9)
Tularemia
28(1)
Anthrax
29(1)
Lessons Learned from Developing Animal Models for Therapeutic Purposes against Biothreat Agents
30(2)
References
32(7)
3 Ethical and Regulatory Challenges in the Development of Countermeasures
39(12)
History of the Animal Rule and Ethical Considerations
39(5)
The Low Approval Rate to Date under the Animal Rule
44(2)
Regulation of Drug Development
46(2)
References
48(3)
4 Developing New Animal Models for Biodefense Research
51(10)
Use of Human Data to Improve the Value of Animal Models
52(2)
Interactions with the Food and Drug Administration
54(1)
"Validation" of Animal Models for Biodefense Research
55(1)
Comparative Biology and Compartmentalization in Animal Model Development
56(1)
Optimizing Current Animal Models
57(1)
References
58(3)
5 Alternative Approaches to Animal Testing for Biodefense Countermeasures
61(16)
General Principles of Alternative Approaches
62(2)
Animal Efficacy Studies Are Clinical Trials
64(2)
In Vitro Tools and Replacement Strategies
66(4)
Promises and Challenges for the Future
70(2)
References
72(5)
APPENDICES
A The Animal Rule
77(12)
B Draft Guidance to Industry: Animal Models - Essential Elements to Address Efficacy Under the Animal Rule
89(20)
C Developing Animal Models for use in Animal Rule Licensure: the NIAID Approach
109(14)
D Presentations to the Committee
123(4)
E Statement of Task
127(4)
F About the Authors
131